A Phase 1/2 Study of BGB-11417 Given Alone and With Carfilzomib and/or Dexamethasone to Treat Multiple Myeloma

Full Title

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and t(11;14)

Purpose

Researchers want to learn if BGB-11417 given alone or with dexamethasone and carfilzomib may help people with multiple myeloma. The people in this study have multiple myeloma that keeps growing after standard treatment. BGB-11417 blocks a protein called Bcl-2 that helps multiple myeloma cells to live and grow.

If you join this study, you will get one of these treatments:

• BGB-11417 alone
• BGB-11417 plus dexamethasone
• BGB-11417 plus dexamethasone and a higher dose of carfilzomib
• BGB-11417 plus dexamethasone and a lower dose of carfilzomib
• Dexamethasone plus a higher dose of carfilzomib

Who Can Join

To join this study, there are a few conditions. You must:

• Have multiple myeloma that came back or keeps growing after treatment.
• Not have received more than 7 prior regimens of therapy for multiple myeloma.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please contact the office of Dr. Malin Hultcrantz 646-608-3714.